Clinical Report: Serenoa repens Extract for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Overview

This multicenter, randomized, double-blind, placebo-controlled trial evaluated the safety and efficacy of Serenoa repens extract (SRE) in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Results demonstrated that SRE significantly improved NIH-CPSI total scores and related symptom domains compared to placebo, with a favorable safety profile.

Background

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common, multifactorial condition characterized by pelvic pain, urinary symptoms, and sexual dysfunction. Current evidence-based treatments are limited, and phytotherapeutic agents like Serenoa repens extract have shown potential benefits. However, large-scale, placebo-controlled trials assessing SRE's efficacy and safety in CP/CPPS are scarce. This study aimed to fill this gap by conducting a rigorous phase 4 clinical trial across multiple centers.

Data Highlights

Key Findings

• SRE treatment led to a statistically significant greater reduction in NIH-CPSI total scores compared to placebo over 12 weeks.
• Improvements were observed in pain, urinary symptoms, and quality of life domains of NIH-CPSI with SRE.
• Clinical response, defined as a ≥6 point improvement in NIH-CPSI, was more frequent in the SRE group.
• SRE was well tolerated with a low incidence of mild adverse events comparable to placebo.
• Randomization and blinding were rigorously maintained to reduce bias.
• Subgroup analyses excluded mild baseline symptom patients due to small numbers but confirmed efficacy in moderate to severe cases.

Clinical Implications

Serenoa repens extract represents a safe and effective phytotherapeutic option for men with moderate to severe CP/CPPS, improving pain, urinary symptoms, and quality of life. Clinicians may consider SRE as part of a multimodal management strategy, especially when conventional therapies are inadequate or contraindicated. Ongoing monitoring for adverse events remains important despite the favorable safety profile.

Conclusion

This large, well-designed trial provides robust evidence supporting the use of Serenoa repens extract in improving symptoms and quality of life in CP/CPPS patients, with minimal safety concerns. These findings reinforce the role of phytotherapy as a valuable adjunct in CP/CPPS management.

References

1. NIH Classification and CP/CPPS Overview
2. Nickel et al. 2001 -- Clinical response definition in CP/CPPS
3. Previous Phytotherapy Studies (Cernilton, Quercetin, Pollen Extract)
4. Current Study Protocol and Results